Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Ashion sales and marketing update

    Ashion PMed Management LLC, Phoenix, Ariz. Business: Genomics Ashions Ashion Analytics LLC subsidiary launched the Genomic Enabled Machine (GEM) Cancer Panel worldwide for genomic analysis of cancer tumors. The test …

    Published on 9/14/2015
  • AstraZeneca sales and marketing update

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Cancer The U.K.s NICE requested more information from AstraZeneca regarding preliminary draft guidance for Lynparza olaparib for maintenance treatment of …

    Published on 9/14/2015
  • Biocept sales and marketing update

    Biocept Inc. (NASDAQ:BIOC), San Diego, Calif. Business: Diagnostic, Pharmacogenetics Biocept launched the Target Selector assay to improve detection and treatment of solid tumors. The blood-based liquid biopsy detects K…

    Published on 9/14/2015
  • Boehringer Ingelheim, Eli Lilly sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Endocrine/Metabolic, Biosimilars Eli Lilly and Boehringer launched Abasaglar insulin glargine in the U.K. to treat…

    Published on 9/14/2015
  • Breckenridge sales and marketing update

    Breckenridge Pharmaceutical Inc., Boca Raton, Fla. Business: Inflammation, Generics Breckenridge launched azelastine nasal solution, a generic of Astelin from Meda AB (SSE:MEDAA, Solna, Sweden), in the U.S. The …

    Published on 9/14/2015
  • Cancer Genetics sales and marketing update

    Cancer Genetics Inc. (NASDAQ:CGIX), Rutherford, N.J. Business: Diagnostic Blue Cross Blue Shield (BCBS) of Illinois will cover Cancer Genetics cancer diagnostic services. The company said BCBS of Illinois covers over 7.…

    Published on 9/14/2015
  • Celgene, Genentech, AbbVie, J&J, Roche sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Genentech Inc., South San Francisco, Calif. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Roche (SIX:ROG; OTCQX:RHHBY), Basel, …

    Published on 9/14/2015
  • Hetero Drugs sales and marketing update

    Hetero Drugs Ltd., Hyderabad, India Business: Cancer, Biosimilars Hetero launched Maball rituximab in India to treat non-Hodgkins lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Maball is a biosimilar of MabThera…

    Published on 9/14/2015
  • Hospira, Medicines Co. sales and marketing update

    Hospira Inc. (NYSE:HSP), Lake Forest, Ill. The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. Business: Cardiovascular Hospira launched in the U.S. a generic version of Angiomax bivalirudin from The Medicines Co. The …

    Published on 9/14/2015
  • Lundbeck sales and marketing update

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Business: Neurology Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that Brintellix vortioxetine from H. Lundbeck …

    Published on 9/14/2015
  • Novo Nordisk sales and marketing update

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that an additional benefit …

    Published on 9/14/2015
  • ProAxsis sales and marketing update

    ProAxsis, Belfast, U.K. Business: Diagnostic ProAxsis launched ProteaseTag immunoassay kits to detect neutrophil elastase, which the company said is a biomarker of disease activity in cystic fibrosis (CF) and chronic …

    Published on 9/14/2015
  • Sanofi sales and marketing update

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Endocrine/Metabolic Sanofi launched once-daily Toujeo insulin glargine in the U.K. to treat diabetes. The product is a 300 units/mL formulation of insulin …

    Published on 9/14/2015
  • Teva sales and marketing update

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Neurology Teva launched Zecuity sumatriptan in the U.S. for the acute treatment of migraine with or without aura. The wholesale acquisition …

    Published on 9/14/2015
  • Theratechnologies, AOP Orphan sales and marketing update

    Theratechnologies Inc. (TSX:TH), Montreal, Quebec AOP Orphan Pharmaceuticals AG, Vienna, Austria Business: Endocrine/Metabolic Egrifta tesamorelin to treat lipodystrophy in HIV patients is now available in European …

    Published on 9/14/2015
  • Vermillion sales and marketing update

    Vermillion Inc. (NASDAQ:VRML), Austin, Texas Business: Diagnostic Vermillion said it received a positive coverage decision for its OVA1 ovarian cancer test from CareFirst BlueCross BlueShield (BCBS). CareFirst BCBS …

    Published on 9/14/2015
  • Allergan, Regeneron sales and marketing update

    Allergan plc (NYSE:AGN), Dublin, Ireland Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Business: Ophthalmic The U.K.s NICE published two final draft guidances recommending Eylea aflibercept from …

    Published on 9/7/2015
  • Amgen sales and marketing update

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Endocrine/Metabolic Amgen priced cholesterol drug Repatha evolocumab in several European countries. The drug will cost L340.20 ($524.42) for a 28-day supply in …

    Published on 9/7/2015
  • BioMarin sales and marketing update

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Novato, Calif. Business: Musculoskeletal, Endocrine/Metabolic BioMarin introduced the kNOWyourDuchenne patient services program to provide free genetic testing and counseling …

    Published on 9/7/2015
  • Celgene sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Autoimmune The U.K.s NICE issued issued final guidance recommending against use of Otezla apremilast from Celgene to treat chronic plaque psoriasis. NICEs final draft …

    Published on 9/7/2015
  • Celsion, myTomorrows sales and marketing update

    Celsion Corp., (NASDAQ:CLSN), Lawrenceville, N.J. myTomorrows, Amsterdam, the Netherlands Business: Cancer Celsion expanded its early access program for ThermoDox heat-activated liposome to include patients with …

    Published on 9/7/2015
  • Emergent BioSolutions sales and marketing update

    Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. Business: Other Emergent launched its military grade auto-injector Emergard for self-injecting antidotes and other emergency medical treatments. FDA has not approved…

    Published on 9/7/2015
  • Galderma sales and marketing update

    Galderma S.A., Lausanne, Switzerland Business: Dermatology Galderma launched Epiduo Forte adapalene/benzoyl peroxide in the U.S. to treat acne vulgaris. The wholesale acquisition cost (WAC) for 45 g of the product is $…

    Published on 9/7/2015
  • Hemispherx, myTomorrows sales and marketing update

    Hemispherx Biopharma Inc. (NYSE-M:HEB), Philadelphia, Pa. myTomorrows, Amsterdam, the Netherlands Business: Neurology Hemispherx and myTomorrows launched Hemispherxs Ampligen rintatolimod through an early access program…

    Published on 9/7/2015
  • Myriad Genetics sales and marketing update

    Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Business: Diagnostic Myriad said Utahs Medicare administrator Noridian Administrative Services LLC (Fargo, N.D.) issued a final local coverage determination (LCD)…

    Published on 9/7/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993